Pembrolizumab + Sacituzumab tirumotecan + Capecitabine
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Triple-Negative Breast Cancer
Conditions
Triple-Negative Breast Cancer
Trial Timeline
Jun 24, 2024 → Dec 14, 2037
NCT ID
NCT06393374About Pembrolizumab + Sacituzumab tirumotecan + Capecitabine
Pembrolizumab + Sacituzumab tirumotecan + Capecitabine is a phase 3 stage product being developed by Merck for Triple-Negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06393374. Target conditions include Triple-Negative Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06393374 | Phase 3 | Recruiting |
Competing Products
20 competing products in Triple-Negative Breast Cancer